Corcept Therapeutics: Sean Maduck sells 25,000 shares

A former president of Corcept Endocrinology reported sales under a Rule 10b5-1 plan adopted December 8, 2025.

Available on EDGAR 11/04/2026 - 07:27 PM EST Accepted by SEC EDGAR 11/04/2026 - 07:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Corcept Therapeutics Inc. reporting person Sean Maduck, identified as former President, Corcept Endocrinology, exercised options and sold common shares. On November 2, 2026, he exercised 11,841 options at $8.27 per share and sold 11,841 shares at a weighted-average price of $81.4183 per share. On November 3, 2026, he exercised 13,159 options at $8.27 per share and sold 8,617 shares at a weighted-average $82.0198 and 4,542 shares at a weighted-average $82.6756 per share. The sales were made under a Rule 10b5-1 plan adopted December 8, 2025.

Insider Trade Summary 10b5-1

Exercise and Sale: 25,000 shares ($1.84M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Maduck Sean

Role Insider

Sold 25,000 shs ($2.05M)

Approx. gross sale proceeds $2.05M

Approx. exercise cost $207K

Approx. pre-tax spread $1.84M

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy) F13	13,159	$0.00	$0.00
Exercise	Common Stock F1	13,159	$8.27	$109K
Sale	Common Stock F2, F4, F1	8,617	$82.0198	$707K
Sale	Common Stock F2, F5, F1	4,542	$82.6756	$376K
Exercise	Stock option (right to buy) F13	11,841	$0.00	$0.00
Exercise	Common Stock F1, F6	11,841	$8.27	$98K
Sale	Common Stock F2, F3, F1	11,841	$81.4183	$964K
Holding	Common Stock F1, F6	--	--	--
Holding	Common Stock F6, F7	--	--	--
Holding	Common Stock F6, F8	--	--	--
Holding	Common Stock F6, F9	--	--	--
Holding	Common Stock F6, F10	--	--	--
Holding	Common Stock F6, F11	--	--	--
Holding	Common Stock F6, F12	--	--	--

Holdings After Transaction: Stock option (right to buy) — 16,986 contracts (Direct); Common Stock — 13,284 shares (Direct); Common Stock — 116,309 shares (Indirect, See Footnote)

Footnotes (13)

1. F1. Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.12 to $82.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.25 to $82.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.34 to $83.02 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
6. F6. Reflects a transfer of shares of Common Stock between direct and indirect accounts over which the Reporting Person has beneficial ownership. The transfer resulted only in a change in the form of the Reporting Person's beneficial ownership and is exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934, as amended.
7. F7. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
8. F8. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
9. F9. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
10. F10. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
11. F11. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
12. F12. Represents the shares held by SNM 2026-2 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
13. F13. Fully exercisable.

Key Figures

Common shares sold: 25,000 shares Shares sold; weighted-average sale price: 11,841 shares; $81.4183 per share Shares sold; weighted-average sale price: 8,617 shares; $82.0198 per share +4 more

7 metrics

Common shares sold 25,000 shares Across November 2 and November 3, 2026

Shares sold; weighted-average sale price 11,841 shares; $81.4183 per share November 2, 2026

Shares sold; weighted-average sale price 8,617 shares; $82.0198 per share November 3, 2026

Shares sold; weighted-average sale price 4,542 shares; $82.6756 per share November 3, 2026

Options exercised 11,841 options November 2, 2026

Options exercised 13,159 options November 3, 2026

Option exercise price $8.27 per share Options exercised November 2 and November 3, 2026

Key Terms

Rule 10b5-1 plan, weighted average sale price, fully exercisable, unvested restricted stock awards

4 terms

Rule 10b5-1 plan regulatory

"made pursuant to a 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"Represents the weighted average sale price"

fully exercisable financial

"Fully exercisable."

unvested restricted stock awards financial

"shares underlying unvested restricted stock awards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CORT shares did Sean Maduck sell, and at what prices?

Sean Maduck sold 25,000 CORT shares across November 2 and November 3, 2026: 11,841 at a weighted-average $81.4183 per share on November 2, then 8,617 at $82.0198 and 4,542 at $82.6756 per share on November 3. The sales were made under a Rule 10b5-1 plan adopted December 8, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maduck Sean

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		M		11,841	A	$8.27	21,779(1)(6)	D
Common Stock	11/02/2026		S(2)		11,841	D	$81.4183(3)	9,938(1)	D
Common Stock	11/03/2026		M		13,159	A	$8.27	23,097(1)	D
Common Stock	11/03/2026		S(2)		8,617	D	$82.0198(4)	14,480(1)	D
Common Stock	11/03/2026		S(2)		4,542	D	$82.6756(5)	9,938(1)	D
Common Stock								3,346(1)(6)	D
Common Stock								20,487(6)	I	See Footnote(7)
Common Stock								20,570(6)	I	See Footnote(8)
Common Stock								32,252(6)	I	See Footnote(9)
Common Stock								34,000(6)	I	See Footnote(10)
Common Stock								0(6)	I	See Footnote(11)
Common Stock								9,000(6)	I	See Footnote(12)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$8.27	11/02/2026		M			11,841	(13)	02/10/2027	Common Stock	11,841	$0	30,145	D
Stock option (right to buy)	$8.27	11/03/2026		M			13,159	(13)	02/10/2027	Common Stock	13,159	$0	16,986	D

Explanation of Responses:

1. Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.12 to $82.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.25 to $82.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.34 to $83.02 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

6. Reflects a transfer of shares of Common Stock between direct and indirect accounts over which the Reporting Person has beneficial ownership. The transfer resulted only in a change in the form of the Reporting Person's beneficial ownership and is exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934, as amended.

7. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

8. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.

9. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

10. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

11. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

12. Represents the shares held by SNM 2026-2 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

13. Fully exercisable.

Remarks:

Former President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)